


NVALT 18 study:

A randomized phase III study of docetaxel versus intercalated erlotinib docetaxel combination therapy in patients with relapsed EGFR wild type, ALK negative non squamous cell carcinoma.



Primary objective

1. Compare the progression free survival between docetaxel and erlotinib-docetaxel in patients with relapsed EGFR wild type, ALK negative non squamous cell carcinoma patients

Secondary objective

1. To characterize the quantitative and qualitative toxicities of these regimens, response rates and duration of response for responding patients, and survival
2. Pharmacokinetic parameters will be studied for patients on erlotinib, thereby studying the exposure during the course of time, erlotinib chrono-pharmacology, and the influence of genetic and environmental factors in individual patients

Total accrual: 230 patients

Study coordinator: Prof. Dr. J. Aerts j.aerts@erasmusmc.nl
Dr. R. Peric r.peric@erasmusmc.nl

Central Data Management: NVALT Datacenter, Amsterdam,

Contact person: Frauwkje Bessels f.bessels@nki.nl